Sodium-Glucose Cotransporter 2 Inhibitor-Associated “Ketoacidosis” Versus “Diabetic Ketoacidosis”: The Importance of Accurate Terminology

Peri‐procedural ketoacidosis risk with sodium‐glucose cotransporter 2 inhibitor use in people without diabetes

(2023) T. Y. Milder et al.   ANAESTHESIA

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

(2022) Scott D. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin in Patients with Chronic Kidney Disease

(2022)   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

(2021) Stefan D. Anker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ketoacidosis in a non-diabetic lactating woman: A case report and literature review

(2021) Alexandra Kachaner et al.   EUROPEAN JOURNAL OF CLINICAL NUTRITION

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

(2020) Milton Packer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors

(2017) Michelle Isaacs et al.   INTERNAL MEDICINE JOURNAL

Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes

(2016) Ele Ferrannini et al.   DIABETES